JP Morgan Chase
ONCE

JP Morgan Chase’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

JP Morgan Chase’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-499,936
Closed -$48.5M – 6063
2019
Q3 		$48.5M Sell
499,936
-183,079
-27% -$18.3M 0.01% 966
2019
Q2 		$69.8M Sell
683,015
-347,827
-34% -$37.5M 0.01% 809
2019
Q1 		$117M Sell
1,030,842
-1,452,603
-58% -$107M 0.02% 597
2018
Q4 		$97.2M Buy
2,483,445
+155,541
+7% +$6.75M 0.02% 631
2018
Q3 		$127M Buy
2,327,904
+25,337
+1% +$1.73M 0.02% 594
2018
Q2 		$191M Sell
2,302,567
-112,640
-5% -$8.69M 0.04% 453
2018
Q1 		$161M Buy
2,415,207
+175,622
+8% +$10.1M 0.03% 482
2017
Q4 		$115M Buy
2,239,585
+390,597
+21% +$28.1M 0.02% 588
2017
Q3 		$165M Buy
1,848,988
+241,016
+15% +$18.3M 0.04% 464
2017
Q2 		$96.1M Buy
1,607,972
+58,879
+4% +$3.29M 0.02% 632
2017
Q1 		$82.6M Buy
1,549,093
+112,596
+8% +$6.68M 0.02% 698
2016
Q4 		$71.7M Buy
1,436,497
+100,006
+7% +$5.36M 0.02% 716
2016
Q3 		$80.3M Sell
1,336,491
-13,089
-1% -$754K 0.02% 632
2016
Q2 		$69M Buy
1,349,580
+670,360
+99% +$28.6M 0.02% 698
2016
Q1 		$20M Buy
679,220
+86,659
+15% +$2.73M 0.01% 1336
2015
Q4 		$26.8M Buy
592,561
+541,845
+1,068% +$28.4M 0.01% 1141
2015
Q3 		$2.12M Sell
50,716
-39,170
-44% -$2.04M ﹤0.01% 2709
2015
Q2 		$5.42M Buy
89,886
+46,888
+109% +$3.1M ﹤0.01% 2342
2015
Q1 		$3.33M Buy
+42,998
New +$2.48M ﹤0.01% 2599

JP Morgan Chase's ONCE Position: Q4 2019 in Review

JP Morgan Chase sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 499,936 shares — an estimated $48.5M sold.

JP Morgan Chase first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $191M in Q2 2018. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.

  • JP Morgan Chase reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • JP Morgan Chase sold 499,936 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $48.5M.
  • JP Morgan Chase first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
  • JP Morgan Chase's Spark Therapeutics, Inc. Common Stock position peaked at $191M in Q2 2018.
  • 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.

Based on JP Morgan Chase's 13F filing for Q4 2019, filed 11 Feb 2020.